This week’s topics include the surgical treatment of moderate ischemic mitral regurgitation, the Mediterranean diet and telomere length, and more.
You are browsing articles on the topic of General Archives - CardioExchange
I’m glad someone still reads paper journals! (8 Dec 2014)CardioExchange Editors, Staff
In the digital age it’s easy to forget the joyful innocence of physical print.
Following a string of recent successes and favorable publicity for the Mediterranean Diet, a a new study published in The BMJ finds that women who more closely followed a Mediterranean diet had longer telomeres, a key measure of healthy aging. The new report is based on data from 4676 women in the Nurses’ Health Study who completed…
This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.
Epinephrine has been a cornerstone of therapy during cardiac resuscitation after cardiac arrest because of its well-established ability to stimulate the heart and increase the probability of a return of spontaneous circulation (ROSC). In recent years, however, concerns have been raised that people treated with epinephrine may have worse neurological outcomes following their resuscitation. In…
This week’s topics include the PROTECT-AF trial, the association of inpatient vs. outpatient onset of STEMI with treatment and clinical outcomes, and more.
European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)
Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…
Encouraging Results for Two New Drugs for Hyperkalemia (21 Nov 2014)
Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized…
Encouraging Results For Two New Drugs For Hyperkalemia (21 Nov 2014)
Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.